恒瑞医药(01276.HK)：福建盛迪医药“注射用磷罗拉匹坦帕洛诺司琼”药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for its drug application, indicating progress in the drug approval process [1] Group 1: Drug Information - The drug in question is Phosphorapitant Palonosetron Injection (HR20013) [1] - The dosage form is an injection [1] - The acceptance number for the application is CXHS2600019 [1] - The application is currently in the listing phase [1] Group 2: Indication - The proposed indication for the drug is to prevent acute and delayed nausea and vomiting in adult patients caused by moderately emetogenic anticancer drugs [1]